Please login to the form below

Not currently logged in
Email:
Password:

Incisive Health goes international with Brussels office

Follows work for the likes of AbbVie, EFPIA and the Global Lung Cancer Coalition

Incisive Health Bill Morgan Sarah Winstone Mike Birtwistle 
From left: Mike Birtwistle, Sarah Winstone and Bill Morgan

Incisive Health has opened its first office outside the UK on the back of a rapid expansion in its international business.

The London-headquartered policy and communications consultancy's new Brussels office - home to its Incisive Health International arm - is located at Square de Meeûs 35, in the heart of the city's European Quarter.

Founding partner Sarah Winstone said: “Tried and tested quickly becomes tested but tired. Clients have been telling us that international health policy communications needs a shake-up. Incisive Health's approach is tailor-made to do precisely that.”

The move comes in the wake of Incisive's international project work for the likes of 23andMe, AbbVie, EFPIA, the Global Lung Cancer Coalition, Norgine and Roche.

Formed in 2013 by founding partners Mike Birtwistle, Bill Morgan and Sarah Winstone, Incisive Health has since grow into a 21-strong team whose work includes pan-European and global health issues.

Birtwistle said: “The world of health policy is getting smaller and contact with key decision-makers has never been easier. But getting cut-through is more challenging. We founded Incisive Health precisely because we know how to achieve this.”

The agency's expansion plans have also seen it recently appoint Anna Dé as head of international business development to help accelerate its growth. 

She joined Incisive in January from Ogilvy Healthworld Market Access, where she spent three years as associate managing partner, prior she held senior roles at Acumen and Hill+Knowlton Strategies.

Article by
Dominic Tyer

28th April 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....
The concordance conundrum: creating space for open dialogue
Growing numbers of patients want a partnership model with their HCP, whereby both parties are equally involved in the decision-making process. This model has been linked with an increase in...
Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...

Infographics